HC Wainwright & Co. Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $45

Benzinga Newsdesk www.benzinga.com Neutral 64.0%

Neg 0% Neu 64% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Damora Therapeutics (NASDAQ:DMRA) with a Buy rating and announces Price Target of $45.